Cantor analyst Daniel Brims was out pounding the table on Endocyte, Inc. (NASDAQ:ECYT), reiterating an Outperform rating and a $21.
Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, announced financial results for …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Hold rating on Endocyte (NASDAQ:ECYT), as the company released its third-quarter …
In a research published today, Brean Capital analyst Jonathan Aschoff downgraded shares of Endocyte (NASDAQ:ECYT) from a Buy to a Hold rating, on …
In a research note released today, Wedbush analyst David M. Nierengarten reiterated an Outperform rating on Endocyte (NASDAQ:ECYT) with a $26 price target, …
